171 related articles for article (PubMed ID: 35483324)
1. Global Prevalence of Myotonic Dystrophy: An Updated Systematic Review and Meta-Analysis.
Liao Q; Zhang Y; He J; Huang K
Neuroepidemiology; 2022; 56(3):163-173. PubMed ID: 35483324
[TBL] [Abstract][Full Text] [Related]
2. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis.
Crisafulli S; Sultana J; Fontana A; Salvo F; Messina S; Trifirò G
Orphanet J Rare Dis; 2020 Jun; 15(1):141. PubMed ID: 32503598
[TBL] [Abstract][Full Text] [Related]
3. Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland.
Suominen T; Bachinski LL; Auvinen S; Hackman P; Baggerly KA; Angelini C; Peltonen L; Krahe R; Udd B
Eur J Hum Genet; 2011 Jul; 19(7):776-82. PubMed ID: 21364698
[TBL] [Abstract][Full Text] [Related]
4. A Systematic Review and Meta-Analysis of the Prevalence of Congenital Myopathy.
Huang K; Bi FF; Yang H
Front Neurol; 2021; 12():761636. PubMed ID: 34795634
[No Abstract] [Full Text] [Related]
5. Clinical aspects, molecular pathomechanisms and management of myotonic dystrophies.
Meola G
Acta Myol; 2013 Dec; 32(3):154-65. PubMed ID: 24803843
[TBL] [Abstract][Full Text] [Related]
6. Muscle pathology in myotonic dystrophy: light and electron microscopic investigation in eighteen patients.
Nadaj-Pakleza A; Lusakowska A; Sułek-Piątkowska A; Krysa W; Rajkiewicz M; Kwieciński H; Kamińska A
Folia Morphol (Warsz); 2011 May; 70(2):121-9. PubMed ID: 21630234
[TBL] [Abstract][Full Text] [Related]
7. Confirmation of the type 2 myotonic dystrophy (CCTG)n expansion mutation in patients with proximal myotonic myopathy/proximal myotonic dystrophy of different European origins: a single shared haplotype indicates an ancestral founder effect.
Bachinski LL; Udd B; Meola G; Sansone V; Bassez G; Eymard B; Thornton CA; Moxley RT; Harper PS; Rogers MT; Jurkat-Rott K; Lehmann-Horn F; Wieser T; Gamez J; Navarro C; Bottani A; Kohler A; Shriver MD; Sallinen R; Wessman M; Zhang S; Wright FA; Krahe R
Am J Hum Genet; 2003 Oct; 73(4):835-48. PubMed ID: 12970845
[TBL] [Abstract][Full Text] [Related]
8. Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects.
Meola G; Cardani R
Neurol Sci; 2017 Apr; 38(4):535-546. PubMed ID: 28078562
[TBL] [Abstract][Full Text] [Related]
9. A Greek National Cross-Sectional Study on Myotonic Dystrophies.
Papadimas GK; Papadopoulos C; Kekou K; Kartanou C; Kladi A; Nitsa E; Sofocleous C; Tsanou E; Sarmas I; Kaninia S; Chroni E; Tsivgoulis G; Kimiskidis V; Arnaoutoglou M; Stefanis L; Panas M; Koutsis G; Karadima G; Traeger-Synodinos J
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555146
[TBL] [Abstract][Full Text] [Related]
10. Affective symptoms and apathy in myotonic dystrophy type 1 a systematic review and meta-analysis.
van der Velden BG; Okkersen K; Kessels RP; Groenewoud J; van Engelen B; Knoop H; Raaphorst J
J Affect Disord; 2019 May; 250():260-269. PubMed ID: 30870776
[TBL] [Abstract][Full Text] [Related]
11. Supraventricular and Ventricular Arrhythmias Are Related to the Type of Myotonic Dystrophy but Not to Disease Duration or Neurological Status.
Bienias P; Łusakowska A; Ciurzyński M; Rymarczyk Z; Irzyk K; Kurnicka K; Kamińska A; Pruszczyk P
Pacing Clin Electrophysiol; 2016 Sep; 39(9):959-68. PubMed ID: 27444982
[TBL] [Abstract][Full Text] [Related]
12. Speech and language abnormalities in myotonic dystrophy: An overview.
Hanoun S; Sun Y; Ebrahimi F; Ghasemi M
J Clin Neurosci; 2022 Feb; 96():212-220. PubMed ID: 34789418
[TBL] [Abstract][Full Text] [Related]
13. Medication adherence in patients with myotonic dystrophy and facioscapulohumeral muscular dystrophy.
Fitzgerald BP; Conn KM; Smith J; Walker A; Parkhill AL; Hilbert JE; Luebbe EA; Moxley RT
J Neurol; 2016 Dec; 263(12):2528-2537. PubMed ID: 27734165
[TBL] [Abstract][Full Text] [Related]
14. Myotonic dystrophy: emerging mechanisms for DM1 and DM2.
Cho DH; Tapscott SJ
Biochim Biophys Acta; 2007 Feb; 1772(2):195-204. PubMed ID: 16876389
[TBL] [Abstract][Full Text] [Related]
15. Development and Validation of a New Molecular Diagnostic Assay for Detection of Myotonic Dystrophy Type 2.
Valaperta R; Lombardi F; Cardani R; Fossati B; Brigonzi E; Merli I; Sansone V; Merletti G; Spina E; Meola G; Costa E
Genet Test Mol Biomarkers; 2015 Dec; 19(12):703-9. PubMed ID: 26505324
[TBL] [Abstract][Full Text] [Related]
16. Utility and Results from a Patient-Reported Online Survey in Myotonic Dystrophies Types 1 and 2.
Wenninger S; Stahl K; Montagnese F; Schoser B
Eur Neurol; 2020; 83(5):523-533. PubMed ID: 33120389
[TBL] [Abstract][Full Text] [Related]
17. Severity, type, and distribution of myotonic discharges are different in type 1 and type 2 myotonic dystrophy.
Logigian EL; Ciafaloni E; Quinn LC; Dilek N; Pandya S; Moxley RT; Thornton CA
Muscle Nerve; 2007 Apr; 35(4):479-85. PubMed ID: 17230537
[TBL] [Abstract][Full Text] [Related]
18. Myotonic dystrophy type 2 and related myotonic disorders.
Meola G; Moxley RT
J Neurol; 2004 Oct; 251(10):1173-82. PubMed ID: 15503094
[TBL] [Abstract][Full Text] [Related]
19.
Bosè F; Renna LV; Fossati B; Arpa G; Labate V; Milani V; Botta A; Micaglio E; Meola G; Cardani R
Front Neurol; 2019; 10():992. PubMed ID: 31611837
[TBL] [Abstract][Full Text] [Related]
20. A Systematic Review and Meta-analysis on the Epidemiology of the Muscular Dystrophies.
Mah JK; Korngut L; Fiest KM; Dykeman J; Day LJ; Pringsheim T; Jette N
Can J Neurol Sci; 2016 Jan; 43(1):163-77. PubMed ID: 26786644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
